Avacta Group Stock Earnings Reports

Avacta reported progress across its oncology-focused pre|CISION platform with two clinical-stage programs and several near-term catalysts. Lead program faridoxorubicin (FAP‑Dox / AVA6000) has completed Phase Ia and advanced into Phase Ib expansion cohorts; management will present dose‑escalation safety data at ESMO 2025 (Oct) and a larger salivary gland cancer dataset (dose escalation + expansion) in late 2025, with initial triple‑negative breast cancer cohort data expected H1 2026. Second program FAP‑exatecan (AVA6103) showed strong preclinical durability (complete responses in a TOPO1‑resistant PDX model) and remains on track to dose the first patient in Q1 2026, with early human data anticipated late 2026. Financially, cash at 30 June 2025 was £12.65m (not including later sale proceeds), management states a runway into Q1 2026, and the company has renegotiated its convertible bond and raised £6.5m gross to cover near‑term bond payments; bond balance was reduced from £25.5m (30 Jun) to £22.95m (30 Sep). Management is prioritizing partnerships and business development to fund further development, but intends to retain 100% ownership of FAP‑exatecan into the clinic. Key strategic strengths include a sustained‑release IP filing (patent life to ~2045), a Tempus collaboration showing FAP expression in ~90% of solid tumors, and growing industry interest; key risks are a limited near‑term cash runway, dependence on partnerships or financing to progress Phase II/expanded trials, and ongoing market skepticism reflected in the share price.